Clinical Trial Goal
To find out if the combination of golidocitinib and standard chemo is safe and works well to treat AITL, follicular lymphoma or PTCL that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have any of the following that has not yet been treated:
- AITL
- Follicular lymphoma
- PTCL
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cyclophosphamide, doxorubicin and vincristine are chemotherapy (chemo) drugs that block the growth of cancer cells.
Golidocitinib is a small molecule inhibitor that blocks JAK1 in certain cells.
Prednisone is a drug that reduces inflammation.
You’ll get:
Golidocitinib is a small molecule inhibitor that blocks JAK1 in certain cells.
Prednisone is a drug that reduces inflammation.
You’ll get:
- Cyclophosphamide – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Doxorubicin – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Golidocitinib – A pill that you take by mouth 1 time each day
- Prednisone – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Vincristine – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has not yet approved golidocitinib.
Locations
Sponsors
lead: M.D. Anderson Cancer Center
